Drug Trials news from FierceBiotech
News
PTC124 proves promising in cystic fibrosis trial
PTC Therapeutics' PTC124 proved promising in an early stage cystic fibrosis trial in Israel. PTC124 has already spurred tremendous interest as a therapy for Duchenne muscular dystrophy. And the Read more...
Acadia shares plunge on mid-stage trial failure
Shares of Acadia Pharmaceuticals went into free fall this morning after the company announced that one of its schizophrenia drug candidates failed a mid-stage trial. Researchers said that ACP-104 was Read more...
Symphogen inks $330M collaboration pact with Genentech
Denmark's Symphogen has inked a $330 million collaboration deal with Genentech to discover new antibodies for three infectious disease Read more...
Novo Nordisk discontinues Phase III on disappointing results
Concluding that a late-stage trial of its experimental therapy to prevent bleeding in trauma patients was headed to a likely failure, Novo Nordisk discontinued the study of Read more...
BioSante Pharma exploring its strategic alternatives
BioSante Pharmaceuticals has brought in Deutsche Bank to advise the company on its "strategic alternatives." The developer has advanced LibiGel, a topical therapy for female sexual dysfunction, into Read more...
Vertex shares rise on positive data for telaprevir
Vertex Pharmaceuticals saw a significant bump in its share price this morning after researchers released new, mid-stage interim data backing telaprevir for hepatitis C. The company is now penciling Read more...
Inspire Pharma shares soar 75% on CF data
Shares of Durham, NC-based Inspire Pharmaceuticals took off this morning after researchers announced that a late-stage trial of its cystic fibrosis therapy produced promising results. Patients taking Read more...
IRX Therapeutics raises $25M Series A
New York-based IRX Therapeutics announced that it has raised $25 million in a Series A. The new money will be used to further develop IRX's cancer and viral disease product platform, including IRX-2 Read more...
Amgen's D-mab beats Fosamax in trial
In a head-to-head trial, Amgen's twice-yearly osteoporosis drug denosumab outperformed weekly oral doses of Merck's Read more...
ALSO NOTED: FDA, Medicare team up on drug surveillance; Early stage prostate vaccine shows promise; and much more...
> FDA is teaming up with the Center for Medicare and Medicaid Services on data-mining. FDA will be able to probe CMS's patient databases, actively looking for potential safety problems. Next, the Read more...
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets